Journal ArticleDOI
Targeted and multifunctional arene ruthenium chemotherapeutics
Gregory S. Smith,Bruno Therrien +1 more
TLDR
An ever-increasing number of papers dealing with the integration of ruthenium complexes with biologically active molecules to derive bioorganometallic molecules of chemotherapeutic significance have been published in recent years, with the emphasis on the combination of photosensitizers with rutenium complexes for the preparation of novel multifunctional photodynamic therapy agents.Abstract:
The introduction of multifunctionalities for tumour targeting is becoming a popular strategy toward the development of new therapeutic agents. In particular, the multifaceted potential of ruthenium(II)-arene complexes show great promise as chemotherapeutics. An ever-increasing number of papers dealing with the integration of ruthenium complexes with biologically active molecules to derive bioorganometallic molecules of chemotherapeutic significance have been published in recent years. This perspective review presents a short overview of multifunctional ruthenium-based drugs, especially those containing arene ruthenium complexes, with the emphasis on the combination of photosensitizers with ruthenium complexes for the preparation of novel multifunctional photodynamic therapy agents.read more
Citations
More filters
Journal ArticleDOI
The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials
TL;DR: This review focuses on the likely mechanisms of action of ruthenium(ii)-based anticancer drugs and the relationship between their chemical structures and biological properties, and highlights the catalytic activity and the photoinduced activation of r Ruthenium (ii) complexes, their targeted delivery, and their activity in nanomaterial systems.
Journal ArticleDOI
Exploration of the medical periodic table: towards new targets
TL;DR: Progress in identifying and defining target sites has been accelerated recently by advances in proteomics, genomics and metal speciation analysis, and examples of metal compounds and chelating agents (enzyme inhibitors) currently in clinical use, clinical trials or preclinical development are highlighted.
Journal ArticleDOI
Noble metals in medicine: Latest advances
Serenella Medici,Massimiliano Francesco Peana,Valeria Marina Nurchi,Joanna Izabela Lachowicz,Guido Crisponi,Maria Antonietta Zoroddu +5 more
TL;DR: A detailed account of the latest results of metal-based drugs and their potential uses in the cure of severe diseases is provided and the number of published studies in this field is huge.
Journal ArticleDOI
Combination of Ru(II) complexes and light: new frontiers in cancer therapy
TL;DR: The recent achievements in the application of ruthenium complexes as photosensitizers and as photoactivatable prodrugs are presented.
Journal ArticleDOI
The potential of organometallic complexes in medicinal chemistry.
Gilles Gasser,Nils Metzler-Nolte +1 more
TL;DR: This short review presents the specific advantages that organometallic metal complexes have over purely organic and also coordination compounds and illustrates how these particular properties can be put to good use in medicinal chemistry.
References
More filters
Journal ArticleDOI
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
TL;DR: Experimental and computational approaches to estimate solubility and permeability in discovery and development settings are described in this article, where the rule of 5 is used to predict poor absorption or permeability when there are more than 5 H-bond donors, 10 Hbond acceptors, and the calculated Log P (CLogP) is greater than 5 (or MlogP > 415).
Journal ArticleDOI
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
Journal ArticleDOI
The role of porphyrin chemistry in tumor imaging and photodynamic therapy
TL;DR: This critical review is focused on the basic concept of PDT, advantages of long-wavelength absorbing photosensitizers (PS), a brief discussion on recent advances in developing PDT agents, and the various synthetic strategies designed at the Roswell Park Cancer Institute, Buffalo.
Journal ArticleDOI
Organometallic Anticancer Compounds
TL;DR: The quest for alternative drugs to the well-known cisplatin and its derivatives, which are still used in more than 50% of the treatment regimes for patients suffering from cancer, is highly needed, and organometallic compounds have recently been found to be promising anticancer drug candidates.
Journal ArticleDOI
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Claudine Scolaro,Alberta Bergamo,Laura Brescacin,R. Delfino,Moreno Cocchietto,Gábor Laurenczy,Tilmann J. Geldbach,Gianni Sava,Paul J. Dyson +8 more
TL;DR: Results show that these ruthenium(II)-arene complexes can reduce the growth of lung metastases in CBA mice bearing the MCa mammary carcinoma in the absence of a corresponding action at the site of primary tumor growth.